These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10792069)

  • 1. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer.
    Fowler JE; Flanagan M; Gleason DM; Klimberg IW; Gottesman JE; Sharifi R
    Urology; 2000 May; 55(5):639-42. PubMed ID: 10792069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
    Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
    Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.
    Chu FM; Jayson M; Dineen MK; Perez R; Harkaway R; Tyler RC
    J Urol; 2002 Sep; 168(3):1199-203. PubMed ID: 12187267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.
    Shore ND; Chu F; Moul J; Saltzstein D; Concepcion R; McLane JA; Atkinson S; Yang A; Crawford ED
    BJU Int; 2017 Feb; 119(2):239-244. PubMed ID: 26991743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer.
    Fowler JE; Gottesman JE; Reid CF; Andriole GL; Soloway MS
    J Urol; 2000 Sep; 164(3 Pt 1):730-4. PubMed ID: 10953135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer.
    Perez-Marreno R; Chu FM; Gleason D; Loizides E; Wachs B; Tyler RC
    Clin Ther; 2002 Nov; 24(11):1902-14. PubMed ID: 12501882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients.
    Shore N; Mincik I; DeGuenther M; Student V; Jievaltas M; Patockova J; Simpson K; Hu CH; Huang ST; Li Y; Lee Y; Chien B; Mao J
    World J Urol; 2020 Jan; 38(1):111-119. PubMed ID: 30941562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer.
    Sharifi R; Knoll LD; Smith J; Kramolowsky E
    Urology; 1998 Feb; 51(2):271-6. PubMed ID: 9495710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
    Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS
    J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
    Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
    Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
    Heyns CF; Simonin MP; Grosgurin P; Schall R; Porchet HC;
    BJU Int; 2003 Aug; 92(3):226-31. PubMed ID: 12887472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer.
    Sartor O; Dineen MK; Perez-Marreno R; Chu FM; Carron GJ; Tyler RC
    Urology; 2003 Aug; 62(2):319-23. PubMed ID: 12893343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer.
    Spitz A; Young JM; Larsen L; Mattia-Goldberg C; Donnelly J; Chwalisz K
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):93-9. PubMed ID: 22025196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer.
    Yu EY; Getzenberg RH; Coss CC; Gittelman MM; Keane T; Tutrone R; Belkoff L; Given R; Bass J; Chu F; Gambla M; Gaylis F; Bailen J; Hancock ML; Smith J; Dalton JT; Steiner MS
    Eur Urol; 2015 Feb; 67(2):334-41. PubMed ID: 24968970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing advanced prostate cancer with Viadur (leuprolide acetate implant).
    Moul JW; Civitelli K
    Urol Nurs; 2001 Dec; 21(6):385-8, 393-4; quiz 395-6. PubMed ID: 11998504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic (60-week) toxicity study of DUROS leuprolide implants in dogs.
    Cukierski MJ; Johnson PA; Beck JC
    Int J Toxicol; 2001; 20(6):369-81. PubMed ID: 11797819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
    Crawford ED; Moul JW; Sartor O; Shore ND
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan.
    Suzuki K; Namiki M; Fujimoto T; Takabayashi N; Kudou K; Akaza H
    Jpn J Clin Oncol; 2015 Dec; 45(12):1168-74. PubMed ID: 26486824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.